Phase 1 Prostate Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to sign a consent form and follow the study requirements
• Adults aged 18 to 75 years (male or female)
• People with a life expectancy of at least 6 months
• People who are well enough to carry out daily activities with little to no limitation (based on a standard scale used by doctors called the ECOG score of 0–2)
• People with solid tumour cancers where standard treatments have stopped working, including a form of advanced prostate cancer that no longer responds to hormone therapy (mCRPC)
• People with prostate cancer who have very low levels of the hormone testosterone in their blood (at or below 50 ng/dL)
• People with prostate cancer who have at least one detectable tumour spot (either measurable on a scan, or visible on a CT/MRI or bone scan)
• People with other solid tumour cancers who have at least one tumour spot measurable by standard imaging criteria
• People whose side effects from previous cancer treatments have mostly resolved to mild or no symptoms
• People whose blood counts, liver function, kidney function, and heart function meet the specific levels required by the study (the trial site can confirm the exact numbers)
• People (and their partners) who agree to use effective contraception from the time of signing the consent form until 6 months after the last dose of the study drug

Who may not be able to join:

• People who have had a blood-filtering procedure (plasmapheresis) or taken higher-dose steroid medications for more than 3 days in a row within the 14 days before the first dose (short-term steroid use to prevent reactions to contrast dye may be acceptable — confirm with trial site)
• People who have received other cancer treatments or experimental drugs within 28 days (or 5 half-lives, whichever is shorter), or radiation therapy within 14 days, before the first dose
• People who have received antibody-based cancer treatments within 30 days before the first dose
• People who have had a solid organ transplant at any point in the past
• People who have previously been treated with certain targeted therapies or (for other solid tumours) topoisomerase inhibitor drugs — this applies to the early phase of the study (confirm with trial site)
• People who have cancer that has spread to the brain or the lining around the brain
• People with certain heart or blood vessel problems, including: an abnormal heart rhythm reading on an ECG; a serious untreated irregular heartbeat; a heart attack, coronary procedure, or bypass surgery within the past 6 months; severe heart failure; or uncontrolled high blood pressure (systolic at or above 160 mmHg and/or diastolic at or above 100 mmHg)
• People who have breathing difficulties requiring ongoing oxygen, or who have active pneumonia or ongoing lung disease
• People with a history of another cancer, unless it was fully treated and has a very low chance of returning — exceptions may include certain skin cancers and early-stage cervical or breast cancers (confirm with trial site)
• People with serious unhealed wounds, ulcers, or bone fractures, or who have had major surgery within 28 days before the first dose or are expected to need major surgery during the study
• People who have had a known allergic reaction to any ingredient in the study drug DXC008
• People with active hepatitis B or hepatitis C infections that meet specific test result thresholds
• People known to be HIV positive, or who have active syphilis requiring treatment, or possible active tuberculosis
• People who have had active bleeding within 30 days before screening, or who are considered at risk of serious bleeding, or who have a hereditary bleeding or clotting disorder
• People who have had a serious blood clot event (such as stroke, deep vein thrombosis, or pulmonary embolism) within the 6 months before the first dose
• Women who are pregnant or breastfeeding
• People with an active infection requiring treatment, or uncontrolled fluid build-up around the lungs, abdomen, or heart that requires repeated draining, within 2 weeks before the first dose
• People who have received a live vaccine within 28 days before the first dose, or who plan to receive one during the study
• People with other conditions that the trial doctor considers may make participation unsafe or unsuitable

Important: Always verify eligibility with the trial site directly before applying.